PEG-Modified Heme-Albumin Complexes for Aqueous Solubility and Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Heme is a highly hydrophobic molecule with limited aqueous solubility, hindering its therapeutic applications, and existing heme-containing compositions do not effectively harness its anti-inflammatory properties.
Innovation Solution
Forming colloidally stable heme-albumin complexes by non-covalently associating heme with human serum albumin and conjugating hydrophilic polymer chains, such as PEG, to enhance solubility and stability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If heme is used as a therapeutic agent, then anti-inflammatory effects are achieved, but aqueous solubility is poor
Solution Approach 1:
The patent uses human serum albumin (HSA) as an intermediary carrier protein to bind heme, enabling heme to be transported in aqueous solutions. The HSA-heme complex serves as a mediator that delivers heme to target sites while maintaining solubility in blood and aqueous environments, thus resolving the contradiction between therapeutic efficacy and aqueous solubility.
Solution Approach 2:
The patent creates a composite structure by conjugating hydrophilic polymer chains (such as PEG) to the HSA-heme complex. This composite modification enhances the aqueous solubility and colloidal stability of the heme-containing complex, allowing it to remain stable in physiological fluids without precipitating, thereby achieving both therapeutic effect and solubility requirements.
2Quantity of substance
If heme is associated with albumin to improve solubility, then aqueous solubility increases, but colloidal stability is insufficient
Solution Approach 1:
The patent modifies the HSA-heme complex by conjugating hydrophilic polymer chains (e.g., PEG) to create a composite structure. This composite modification enhances colloidal stability by preventing aggregation and precipitation of the heme-albumin complex in aqueous solutions, while maintaining the solubility benefits of the protein carrier.
Solution Approach 2:
The patent alters the physical-chemical parameters of the heme-albumin complex by introducing hydrophilic polymer chains, which changes the surface properties and interaction with aqueous environments. This parameter change enhances colloidal stability by reducing hydrophobic interactions that lead to aggregation, while preserving the solubility improvement achieved through albumin binding.
3Stability of the object's composition
If hydrophilic polymer chains are conjugated to heme-albumin complex, then colloidal stability improves, but manufacturing complexity increases
Solution Approach 1:
The patent uses human serum albumin as an intermediary carrier that facilitates both heme binding and subsequent polymer conjugation. The HSA protein serves as a convenient platform with known binding sites and functional groups that can be modified, simplifying the multi-step process of creating the final stable complex compared to directly modifying free heme.
Solution Approach 2:
The patent performs preliminary binding of heme to albumin under controlled conditions before conjugating polymer chains. This preliminary action establishes a stable protein-heme complex with defined stoichiometry and orientation, making the subsequent polymer conjugation more predictable and controllable, thus managing manufacturing complexity through staged synthesis.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The heme-albumin complexes exhibit improved aqueous solubility and colloidal stability, reducing impurities and maintaining stability for up to 72 hours, enabling effective therapeutic use.
Implementation Method 1
heme was non-covalently associated with the ubiquitous plasma protein human serum albumin (HSA) to form a heme-albumin complex
Implementation Method 2
hydrophilic polymer chains (e.g., poly(ethylene glycol) (PEG) chains) were conjugated to the surface of the heme-albumin complex
Implementation Method 3
filtering the crude colloidally stable heme-albumin complex by ultrafiltration against a filtration membrane, thereby forming a retentate fraction comprising the colloidally stable heme-albumin complex and a permeate fraction comprising low molecular weight contaminants
Data Source
AI summary
Disclosed herein are colloidally stable heme-albumin complexes, as well as compositions comprising these complexes, methods of making these complexes, and methods of using these complexes. These heme-albumin complexes can comprise from three to five heme molecules non-covalently associated with an albumin protein, and a plurality of hydrophilic polymer chains (e.g., polyethylene glycol (PEG) polymer chains) conjugated to the albumin protein.